INTRODUCTION {#s1}
============

Breast cancer is the most common malignant neoplasm among women in the world. It is believed to result from a complex interplay of genetic and non-genetic risk factors. Linkage and family-based studies have shown that germline mutations of high- and moderate-penetrance genes such as *BRCA1/2*, *PTEN*, *ATM*, *CHEK2*, *TP53*, *PALB2*, and *BRIP1* account for 20%--25% of the genetic component of breast cancer \[[@R1]\]. Genetic association studies, such as genome-wide association studies (GWASs), have identified low-penetrance common variants (predominantly single nucleotide polymorphisms \[SNPs\]) associated with breast cancer risk. Since the first 3 GWASs that identified SNPs associated with breast cancer susceptibility were conducted in early 2007 \[[@R2]--[@R4]\], over 80 loci associated with increased breast cancer risk have been found \[[@R5]--[@R16]\]. These studies have suggested that high- and moderate-penetrance genes and GWAS-identified low-penetrance common variants together may explain about 50% of the familial risk of breast cancer \[[@R17]\].

Accumulating evidence has shown that certain genetic variations are associated with response to chemotherapy in patients with lung cancer \[[@R18], [@R19]\]. However, genetic variants associated with tumor response to specific chemotherapy regimens in breast cancer have rarely been studied \[[@R20]--[@R22]\]. Neoadjuvant chemotherapy is increasingly used for operable primary breast cancer because it yields survival rate at least equal to those of adjuvant chemotherapy \[[@R23]--[@R25]\]. Some of the most effective cytotoxic agents against breast cancer are the anthracyclines, which have formed the backbone of most adjuvant and neoadjuvant regimens for more than 2 decades \[[@R23], [@R26]--[@R29]\]. Another class of effective cytotoxic agents, taxanes (such as paclitaxel and docetaxel), are also used as standard therapy for breast cancer, as monochemotherapy, in combination therapy, or in sequential therapy \[[@R30]--[@R32]\]. As neoadjuvant therapy, taxanes have produced dramatic increases in response rates \[[@R33]--[@R35]\]. Still, only a minority of patients achieve pathologic complete response (pCR) after receiving either anthracycline- or taxane-based neoadjuvant regimens. Given the lack of a preferred neoadjuvant treatment regimen, identifying which patients are most likely to respond to a specific regimen could significantly improve breast cancer treatment outcomes and facilitate the development of targeted therapies. Since GWASs have been successful in identifying low-penetrance common variants for breast cancer predisposition, several studies have investigated the potential roles of GWAS-identified SNPs in the choice of neoadjuvant therapy and evaluation of patient prognosis \[[@R18], [@R19]\]. In the current GWAS, we aimed to identify associations between SNPs associated with breast cancer susceptibility and response to anthracycline- and taxane-based neoadjuvant chemotherapy in patients with breast cancer.

RESULTS {#s2}
=======

Patient characteristics {#s2_1}
-----------------------

The demographic and clinicopathologic characteristics of the 960 breast cancer patients who received neoadjuvant chemotherapy and were included in the discovery or validation cohort are shown in Table [1](#T1){ref-type="table"}. In the discovery stage, the pCR rate was 32.6%. In the validation stage, the pCR rate was 15.5% in patients who received anthracycline-based neoadjuvant therapy and 17.1% in those who received a taxane-based regimen.

###### Patient characteristics

  Characteristic                 No. of patients   Discoverycohort (*N* = 92)   Validation cohort   *P* value                             
  ------------------------------ ----------------- ---------------------------- ------------------- ----------- ----- ------ ----- ------ ---------------------------------------------
  Age (years)                                                                                                                             
   ≤ 50                          571               59.5                         65                  70.7        250   62.3   256   54.8   0.006[\*](#tfn_001){ref-type="table-fn"}
   \> 50                         389               40.5                         27                  29.3        151   37.7   211   45.2   
  Tumor size                                                                                                                              
  ≤ 2cm                          381               40.0                         22                  23.9        147   37.3   212   45.5   \< 0.001[\*](#tfn_001){ref-type="table-fn"}
  \> 2cm                         571               60.0                         70                  76.1        247   62.7   254   54.5   
  Unknown                        8                                              0                               7            1            
  Tumor grade                                                                                                                             
   I                             95                10.3                         6                   6.7         45    11.6   44    9.8    0.21
   II                            691               74.7                         68                  76.4        277   71.2   346   77.4   
   III                           139               15.0                         15                  16.9        67    17.2   57    12.8   
   Unknown                       35                                             3                               12           20           
  Lymph node involvement                                                                                                                  
   Negative                      525               55.4                         63                  69.2        230   57.6   232   50.7   0.002[\*](#tfn_001){ref-type="table-fn"}
   Positive                      423               44.6                         28                  30.8        169   42.4   226   49.3   
   Unknown                       12                                             1                               2            9            
  Estrogen receptor status                                                                                                                
   Negative                      377               39.4                         44                  48.4        155   38.8   178   38.2   0.18
   Positive                      579               60.6                         47                  51.6        244   61.2   288   61.8   
   Unknown                       4                                              1                               2            1            
  Progesterone receptor status                                                                                                            
   Negative                      479               50.2                         51                  56.7        206   51.6   222   47.7   0.23
   Positive                      475               49.8                         39                  43.3        193   48.4   243   52.3   
   Unknown                       6                                              2                               2            2            
  HER2 status                                                                                                                             
   Negative                      694               72.4                         56                  61.5        296   73.8   342   73.4   0.05
   Positive                      264               27.6                         35                  38.5        105   26.2   124   26.6   
   Unknown                       2                                              1                               0            1            
  Surgery type                                                                                                                            
   BCS                           406               42.3                         51                  55.4        171   42.6   184   39.4   0.017[\*](#tfn_001){ref-type="table-fn"}
   Mastectomy                    554               57.7                         41                  44.6        230   57.4   283   60.6   
  Chemotherapy cycles                                                                                                                     
   ≥ 4                           897               93.4                         92                  100.0       361   90.0   444   95.1   \< 0.001[\*](#tfn_001){ref-type="table-fn"}
   \< 4                          63                6.6                          0                   0.0         40    10.0   23    4.9    
  Adjuvant chemotherapy                                                                                                                   
   No                            332               34.6                         15                  16.3        113   28.2   204   43.7   \< 0.001[\*](#tfn_001){ref-type="table-fn"}
   Yes                           628               65.4                         77                  83.7        288   71.8   263   56.3   
  Adjuvant endocrine therapy                                                                                                              
   No                            395               41.1                         35                  38.0        162   40.4   198   42.4   0.68
   Yes                           565               58.9                         57                  62.0        239   59.6   269   57.6   
  Pathologic complete response                                                                                                            
   non-pCR                       788               82.1                         62                  67.4        339   84.5   387   82.9   \< 0.001[\*](#tfn_001){ref-type="table-fn"}
   pCR                           172               17.9                         30                  32.6        62    15.5   80    17.1   

HER2, human epidermal growth factor receptor 2; BCS, breast-conserving surgery; pCR, pathologic complete response

A *P* value \< 0.05 was considered statistically significant.

Identification of SNPs {#s2_2}
----------------------

The discovery cohort included 92 patients who each received 4 cycles of the anthracycline-based CTF neoadjuvant regimen. pCR was used to differentiate cases from controls. All individuals had \< 10% of missing genotypes, and all were genotyped as females based on X-chromosome genotypes, and therefore all were included. GWAS was performed using PLINK on genotype data from 30 patients with pCR and 62 patients with non-pCR. Of 389,795 SNPs included in the analysis, 351 SNPs showed significant associations with pCR. We then employed 3 additional criteria to select SNPs for inclusion in the validation stage. First, the 351 SNPs that showed significant association with pCR were confirmed using a genome-wide significance at *P* \< 1e-03 (Figure [1](#F1){ref-type="fig"}). Second, the data set was narrowed down to 32 SNPs that are known to be related to genes that correlate with cancer using a search of gene annotation databases and published literature (ORs ranging from 2.89 \[95% CI, 1.53--5.48\] to 6.14 \[95% CI, 2.07--18.20\]) (Table [2](#T2){ref-type="table"}). Third, using unadjusted univariate Cox proportional hazard models (*P* \< 0.05), we ended up with only 2 SNPs with a pCR rate that was significantly higher for both homozygotes (Table [3](#T3){ref-type="table"}).

![Scatter plot of *P* values (shown as -log10) in association test of 389,795 single nucleotide polymorphismalleles with pathologic response status at the end of anthracycline-based neoadjuvant chemotherapy in discovery cohort of 92 breast cancer patients. Colors indicate chromosomes](oncotarget-07-5042-g001){#F1}

###### SNPs significantly associated with breast cancer in patients who received anthracycline-based CTF chemotherapy regimens in discovery cohort

                  MAF                                                                                                     
  --------------- ------- -------- -------------- ------------ ------------ ---------- ---------- ----------------------- ------------------------------------------------------
  rs6135795       G       20       16534948       KIF16B       Intron       0.62       0.28       4.07 (2.11--7.83)       1.61 × 10^−5^[\*](#tfn_002){ref-type="table-fn"}
  rs4748316       T       10       16779881       RSU1         Intron       0.48       0.18       4.17 (2.10--8.27)       2.55 × 10^−5^[\*](#tfn_002){ref-type="table-fn"}
  rs6686072       C       1        57936193       DAB1         Intron       0.40       0.13       4.33 (2.07--9.06)       4.98 × 10^−5^[\*](#tfn_002){ref-type="table-fn"}
  rs687660        A       11       70111532       PPFIA1       Upstream     0.32       0.08       5.10 (2.19--11.87)      5.97 × 10^−5^[\*](#tfn_002){ref-type="table-fn"}
  rs3102072       A       1        20964066       PINK1        Intron       0.62       0.31       3.61 (1.89--6.90)       7.39 × 10^−5^[\*](#tfn_002){ref-type="table-fn"}
  **rs6044100**   **T**   **20**   **16524972**   **KIF16B**   **Intron**   **0.42**   **0.15**   **4.05 (1.98--8.29)**   **7.65 × 10^−5^**[\*](#tfn_002){ref-type="table-fn"}
  rs9806453       G       15       60943845       RORA         Intron       0.67       0.37       3.46 (1.80--6.64)       1.43 × 10^−4^[\*](#tfn_002){ref-type="table-fn"}
  rs6075070       G       20       16536424       KIF16B       Intron       0.42       0.16       3.80 (1.87--7.72)       1.44 × 10^−4^[\*](#tfn_002){ref-type="table-fn"}
  rs4811431       T       20       52031569       TSHZ2        Intron       0.28       0.08       4.88 (2.02--11.77)      1.78 × 10^−4^[\*](#tfn_002){ref-type="table-fn"}
  rs4580153       T       16       81817239       PLCG2        Intron       0.32       0.10       4.17 (1.86--9.35)       2.84 × 10^−4^[\*](#tfn_002){ref-type="table-fn"}
  rs12481468      C       20       43532438       YWHAB        intron       0.22       0.04       6.14(2.07--18.20)       3.16 × 10^−4^[\*](#tfn_002){ref-type="table-fn"}
  **rs1799937**   **A**   **11**   **32410774**   **WT1**      **Intron**   **0.47**   **0.21**   **3.33 (1.70--6.51)**   **3.38 × 10^−4^**[\*](#tfn_002){ref-type="table-fn"}
  rs1004895       A       20       16540600       KIF16B       Intron       0.40       0.16       3.54 (1.74--7.22)       3.38 × 10^−4^[\*](#tfn_002){ref-type="table-fn"}
  rs32496         A       5        55641639       MAP3K1       Upstream     0.68       0.40       3.24 (1.68--6.23)       3.38 × 10^−4^[\*](#tfn_002){ref-type="table-fn"}
  rs16944877      C       12       115459615      TBX3         Upstream     0.35       0.13       3.77 (1.77--8.04)       3.74 × 10^−4^[\*](#tfn_002){ref-type="table-fn"}
  rs12530912      G       7        116127529      CAV2         Intron       0.28       0.08       4.35 (1.85--10.25)      3.96 × 10^−4^[\*](#tfn_002){ref-type="table-fn"}
  rs17191246      C       15       60386336       ANXA2        Downstream   0.27       0.08       4.49 (1.85--10.90)      4.56 × 10^−4^[\*](#tfn_002){ref-type="table-fn"}
  rs10443217      G       1        57979666       DAB1         Intron       0.38       0.14       3.64 (1.73--7.66)       4.58 × 10^−4^[\*](#tfn_002){ref-type="table-fn"}
  rs1620195       T       12       32084747       H3F3C        Upstream     0.42       0.18       3.37 (1.68--6.76)       4.58 × 10^−4^[\*](#tfn_002){ref-type="table-fn"}
  rs10493224      A       1        57938752       DAB1         Intron       0.25       0.07       4.67 (1.85--11.77)      5.14 × 10^−4^[\*](#tfn_002){ref-type="table-fn"}
  rs4833326       C       4        126424441      FAT4         Downstream   0.67       0.40       3.00 (1.57--5.74)       7.41 × 10^−4^[\*](#tfn_002){ref-type="table-fn"}
  rs1467089       T       8        49960530       SNAI2        Upstream     0.40       0.17       3.27 (1.61--6.62)       7.52 × 10^−4^[\*](#tfn_002){ref-type="table-fn"}
  rs12151836      G       2        86601052       KDM3A        Upstream     0.28       0.09       3.92 (1.70--9.04)       8.24 × 10^−4^[\*](#tfn_002){ref-type="table-fn"}
  rs17588172      G       7        116154015      CAV2         Downstream   0.28       0.09       3.92 (1.70--9.04)       8.24 × 10^−4^[\*](#tfn_002){ref-type="table-fn"}
  rs4631527       G       9        110270036      KLF4         Upstream     0.57       0.31       2.93 (1.55--5.57)       8.29 × 10^−4^[\*](#tfn_002){ref-type="table-fn"}
  rs10857592      C       10       49732975       ARHGAP22     Intron       0.24       0.07       4.46 (1.75--11.36)      9.02 × 10^−4^[\*](#tfn_002){ref-type="table-fn"}
  rs1080954       T       20       16506016       KIF16B       Intron       0.47       0.23       3.01 (1.55--5.85)       9.07 × 10^−4^[\*](#tfn_002){ref-type="table-fn"}
  rs3821629       C       3        25620132       RARB         Intron       0.52       0.27       2.94 (1.54--5.62)       9.17 × 10^−4^[\*](#tfn_002){ref-type="table-fn"}
  rs3019286       A       8        99895405       STK3         Intron       0.60       0.34       2.89 (1.53--5.48)       9.59 × 10^−4^[\*](#tfn_002){ref-type="table-fn"}
  rs12039126      A       1        56681381       PPAP2B       Downstream   0.27       0.08       4.00 (1.69--9.49)       9.73 × 10^−4^[\*](#tfn_002){ref-type="table-fn"}
  rs7307249       G       12       117077849      MAP1LC3B2    Downstream   0.37       0.15       3.28 (1.59--6.78)       9.80 × 10^−4^[\*](#tfn_002){ref-type="table-fn"}
  rs527912        A       1        20934283       CDA          Intron       0.43       0.20       3.06 (1.55--6.03)       9.85 × 10^−4^[\*](#tfn_002){ref-type="table-fn"}

SNP, single nucleotide polymorphism; CTF, 5-fluorouracil, pirarubicin, and cyclophosphamide; Chr., chromosome; MAF, minor allele frequency; pCR, pathologic complete response; OR, odds ratio; CI, confidence interval

A *P* value \< 0.05 was considered statistically significant.

The two SNPs examined in the validation phase were marked by bold.

###### SNPs for which homozygosity was significantly associated with pCR in the discovery cohort

  SNP         Genotype   No. (*N* = 92)   \%     Pathologic response   *P* value               
  ----------- ---------- ---------------- ------ --------------------- ----------- ---- ------ ---------------------------------------------------------------------------------
  rs1799937   A A        10               10.9   4                     40.0        6    60.0   0.002[\*](#tfn_003){ref-type="table-fn"}[^a^](#tfn_004){ref-type="table-fn"}
              G A        34               37.0   18                    52.9        16   47.1   
              G G        48               52.2   40                    83.3        8    16.7   
  rs6044100   C C        55               59.8   46                    83.6        9    16.4   \< 0.001[\*](#tfn_003){ref-type="table-fn"}[^b^](#tfn_005){ref-type="table-fn"}
              T C        30               32.6   14                    46.7        16   53.3   
              T T        7                7.6    2                     28.6        5    71.4   

SNP, single nucleotide polymorphism; pCR, pathologic complete response

A *P* value \< 0.05 was considered statistically significant

AA vs GG in rs11799937

CC vs TT in rs6044100.

One of these two SNPs, rs1799937, is located in an intron of the *WT1* gene at 11p13; the A allele had an OR of 3.33 (95% CI, 1.70--6.51) compared with the G allele. The other SNP, rs6044100, is located in an intron of the *KIF16B* gene at 20p11, and the T allele had an OR of 4.05 (95% CI, 1.98--8.29) compared with the C allele. We found significantly higher pCR rates in patients with the rs1799937 AA genotype (60.0%) and the rs6044100 TT genotype (71.4%) than in patients with the rs1799937 GG genotype (16.7%) and the rs6044100 CC genotype (16.4%) (Table [3](#T3){ref-type="table"}).

Association of rs1799937genotype and response to anthracycline-based regimens {#s2_3}
-----------------------------------------------------------------------------

Having confirming that the SNPs rs1799937 AA genotype and rs6044100 TT genotype are associated with pCR, we investigated the potential association between these two genetic variants and pCR after anthracycline-based neoadjuvant chemotherapy. We attempted to validate rs1799937 and rs6044100 in an independent cohort of 401 patients who received CTF regimens by sequencing analysis. The results showed that patients with the rs1799937 AA genotype benefited from anthracycline-based neoadjuvant chemotherapy more than patients with the GG genotype; the pCR rates of the AA versus GG genotypes were 26.7% and 11.5%, respectively (*P* = 0.035). Logistic regression models showed an odds ratio for patients with the rs1799937 AA genotype compared with those with the GG genotype of 2.81 (95% CI, 1.13--6.98; *P* = 0.026, Table [4](#T4){ref-type="table"}). However, no association was identified between rs6044100 and pCR; the pCR rates after CTF therapy for patients with the TT genotype versus those with the CC genotype were 18.8% and 15.2%, respectively (*P* = 0.86).

###### Associations between SNP genotypes and pCR in 401 validation cohort patients who underwent anthracycline-based (CTF) chemotherapy. Two SNPs were examined

  SNP         Genotype   No. (*N* = 401)   \%     Pathologic response   *P* value   OR (95%CI)   *P* value                                                                 
  ----------- ---------- ----------------- ------ --------------------- ----------- ------------ ----------- ------------------------------------------ ------------------ ------------------------------------------------------------------------------
  rs1799937   A A        30                7.5    22                    73.3        8            26.7        0.035[\*](#tfn_006){ref-type="table-fn"}   2.81(1.13--6.98)   0.026[\*](#tfn_006){ref-type="table-fn"}[^a^](#tfn_007){ref-type="table-fn"}
              G A        153               38.2   124                   81          29           19                                                     1.81(1.01--3.23)   0.046[\*](#tfn_006){ref-type="table-fn"}[^b^](#tfn_008){ref-type="table-fn"}
              G G        218               54.4   193                   88.5        25           11.5                                                                      
  rs6044100   C C        224               57.3   190                   84.8        34           15.2        0.86                                       0.78(0.30--2.03)   0.60[^c^](#tfn_009){ref-type="table-fn"}
              T C        135               34.5   113                   83.7        22           16.3                                                   0.84(0.31--2.29)   0.74[^d^](#tfn_010){ref-type="table-fn"}
              T T        32                8.2    26                    81.2        6            18.8                                                                      
              Unknown    10                       10                                0                                                                                      

SNP, single nucleotide polymorphism; pCR, pathologic complete response; CTF, 5-fluorouracil, pirarubicin, and cyclophosphamide; OR, odds ratio; CI, confidence interval

A *P* value of \< 0.05 was considered statistically significant.

AA vs GG

AG vs GG

CC vs TT

CT vs TT.

Association between rs1799937genotype and response to taxane-based regimens {#s2_4}
---------------------------------------------------------------------------

Further, we explored the association of rs1799937 with pCR in patients receiving taxane-based neoadjuvant chemotherapy. Rs1799937 genotypes were assessed by sequencing in an independent cohort of 467 patients who received taxane-based regimens. No association was observed between rs1799937 genotype and pCR status; the two homozygous genotypes showed similar pCR rates (17.1% vs 19.5%; *P* = 0.34, Table [5](#T5){ref-type="table"}).

###### Associations between SNP genotypes and pCR in 467 validation cohort patients who underwent taxane-based chemotherapy

  SNP         Genotype   No.(*N* = 467)   \%     Pathologic response   *P* value   OR (95%CI)   *P* value                              
  ----------- ---------- ---------------- ------ --------------------- ----------- ------------ ----------- ------ ------------------- ------------------------------------------
  rs1799937   A A        41               8.8    34                    82.9        7            17.1        0.34   0.85 (0.36--2.04)   0.72[^a^](#tfn_012){ref-type="table-fn"}
              G A        185              39.6   159                   85.9        26           14.1               0.68 (0.40--1.14)   0.14[^b^](#tfn_013){ref-type="table-fn"}
              G G        241              51.6   194                   80.5        47           19.5                                   

pCR, pathologic complete response; SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval

A *P* value of \< 0.05 was considered statistically significant.

AA vs GG

GA vs GG.

Association between rs1799937genotype and survival {#s2_5}
--------------------------------------------------

Among the 493 patients who received CTF regimen, including 92 from the discovery stage and 401 from the validation stage, patients with the rs1799937 AA genotype had a slightly higher but not statistically significant 5-year recurrence-free survival (RFS) rate (89.3%; 95% CI, 79.5%-99.1%; AA vs GA+GG; *P* = 0.35) and 5-year distant recurrence-free survival (DRFS) rate (92.2%; 95% CI, 83.8%-100.1%; AA vs GA+GG; *P* = 0.31) than those with the rs1799937 GG genotype (RFS, 84.0%; 95% CI, 79.1%-88.9%; DRFS, 87.4%; 95% CI, 82.9%-91.9%; Figures [2a and 2b](#F2){ref-type="fig"}). However, no difference in RFS and DRFS was detected between rs1799937 AA versus GG genotype in the 467 breast cancer patients treated with taxane-based neoadjuvant chemotherapy (Figures [2c and 2d](#F2){ref-type="fig"}).

![Kaplan-Meier estimates of recurrence-free survival (RFS) and distant recurrence-free survival (DRFS) by rs1799937 genotype and neoadjuvant chemotherapy regimen\
**Panel A.** 10-year RFS by rs1799937 genotype in patients receiving anthracycline-based regimen. **Panel B.** 10-year DRFS by rs1799937 genotype in patients receiving anthracycline-based regimen. **Panel C.** 10-year RFS by rs1799937 genotype in patients receiving taxane-based regimen. **Panel D.** 10-year DRFS by rs1799937 genotype in patients receiving taxane-based regimen.](oncotarget-07-5042-g002){#F2}

DISCUSSION {#s3}
==========

We performed a GWAS to assess genetic variants that may be associated with pCR in patients receiving neoadjuvant chemotherapy for breast cancer. We identified 1 SNP, rs1799937 A \> G, as a genetic variant associated with response to anthracycline-based CTF neoadjuvant chemotherapy. Patients with the rs1799937 AA genotype showed significantly higher rates of pCR and better prognosis after treatment with CTF than patients with the GG genotype. However, we found that the AA allele of rs1799937 was not associated with sensitivity to taxane-based neoadjuvant chemotherapy regimens.

The rs1799937 A \> G SNP is located in an intron region of the *WT1* gene at 11p13. *WT1* encodes a transcription factor that contains 4 zinc-finger motifs at the C-terminus and plays an important role in organ development and cell survival \[[@R36]\]. In addition to regulating nuclear transcription, *WT1* is also involved in RNA splicing and metabolism \[[@R37], [@R38]\]. *WT1* was first identified as a tumor suppressor gene in Wilms\' tumor. However, accumulating evidence has shown that overexpression of *WT1* exerts an oncogenic effect in other tumors \[[@R36], [@R39], [@R40]\] and is linked to poor prognoses in leukemia and breast cancer \[[@R41], [@R42]\].

Previous studies have also shown that *WT1* gene expresion is related to sensitivity to chemotherapy. Perugorria et al. have reported that *WT1* knockdown markedly sensitized hepatocellular carcinoma cell lines to doxorubicin-induced apoptosis \[[@R43]\]. Interestingly, the effect of *WT1* expression on apoptosis of hepatocellular carcinoma cells seems to be specific to doxorubicin, and not to other chemotherapeutic agents. Doxorubicin, an anthracycline, is a potent inhibitor of Top2 isozymes and exerts its genotoxic effect by impeding DNA duplication \[[@R44]--[@R36]\]. We speculate that rs1799937 may function by altering *WT1* gene expression, thus rendering cancer cells in patients with the AA allele more sensitive to anthracycline-based chemotherapy.

In summary, our results indicate that anthracycline-based neoadjuvant chemotherapy may benefit breast cancer patients with the rs1799937 AA allele more than those with the GG allele. Therefore, further investigation of *WT1* as a potential target of chemotherapy for breast cancer is warranted.

MATERIALS AND METHODS {#s4}
=====================

Patient selection {#s4_1}
-----------------

The GWAS included 960 patients with breast cancer who were treated at Peking University Cancer Hospital between October 2003 and November 2011. Written informed consent was obtained from all patients, and this study was approved by the Research and Ethical Committee of Peking University Cancer Hospital.

The discovery stage included 92 patients from a pool of 493 patients who had received 4 cycles of an anthracycline-based neoadjuvant regimen consisting of cyclophosphamide, pirarubicin (THPADM), 5-fluorouracil (CTF). This regimen included pirarubicin 35 mg/m^2^ i.v. on day 1 and day 8, cyclophosphamide 500 mg/m^2^ i.v. on day 1 and day 8, and 5-fluorouracil 200 mg/m^2^/day i.v. continuous infusion for 28 days, every 4 weeks. All the 92 patients received an identical CTF regimen with the same dosage and same number of cycles. There was no bias in terms of any patient characteristics. Using pCR, defined as the absence of invasive breast tumor cells in the breast and axillary lymph nodes after completion of neoadjuvant chemotherapy, the patients were divided into 2 pathologic response groups with 30 in the pCR group and 62 in the non-pCR group. In the validation stage, 401 patients who had received 2--6 cycles of CTF and 467 patients who had received a taxane-based regimen using paclitaxel were included.

Genotyping methods and quality control {#s4_2}
--------------------------------------

In the discovery stage, we isolated DNA from peripheral blood lymphocytes using phenol-chloroform extraction and ultrapurification. Genotyping was conducted using Affymetrix Genome-Wide Human SNP Array 6.0 chips (Santa Clara, CA). We performed systematic quality control on the raw genotyping data to filter out unqualified samples and SNPs. As quality control, we excluded DNA samples that failed to be genotyped as female based on X-chromosome genotypes. SNPs were excluded if (1) they were not mapped on autosomal chromosomes; (2) they had a call rate \< 95%; (3) they had minor allele frequency \< 0.01; (4) they deviated from the Hardy-Weinberg equilibrium at *P* \< 1e^−^05; or (5) their genotyping clusters had poor resolution. These led to a total of 389,795 SNPs to be analyzed using a GWAS toolset PLINK \[[@R47]\].

The genotypes of the patients with and without pCR were compared. We selected SNPs that were (1) associated with pCR in the discovery stage at *P* \< 1e-03; (2) located in genes that have been correlated with cancer in gene annotation databases and published literature; and (3) associated with pCR status in the discovery stage at *P* \< 0.05 using unadjusted univariate Cox proportional hazard models. Finally, 2 SNPs, rs1799937 and rs6044100, were identified.

For the validation phase, genomic DNA samples were extracted from peripheral blood lymphocytes of an additional 868 patients, including 401 who received anthracyclin-based regimens and 467 who received taxane-based regimens. Genotyping of the samples was conducted using a polymerase chain reaction/sequencing assay (ABI 3730 system, Applied Biosystems, Foster City, CA).

Statistical analysis {#s4_3}
--------------------

Association between SNPs and response to neoadjuvant chemotherapy in patients with breast cancer was assessed using logistic regression models and reported as odds ratios (ORs) and 95% confidence intervals (CIs). ORs were estimated for heterozygotes and homozygotes for the variant allele compared with homozygotes for the common allele. A logistic regression model was applied to determine whether a factor was an independent predictor of pCR in a multivariate analysis. Survival analysis was performed using the Kaplan-Meier curves. All statistical tests were two-sided. All statistical analyses were performed using SPSS 16.0 software (SPSS Inc., Chicago, IL).
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:   genome-wide association study

SNP

:   single nucleotide polymorphism

pCR

:   pathologic complete response

CTF

:   5-fluorouracil, pirarubicin, and cyclophosphamide
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:   odds ratio
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RFS

:   recurrence-free survival

DRFS

:   distant recurrence-free survival
